Tag: Vaccine

  • Early COVID-19 Vaccine ‘likely to be imperfect’: UK Task Force

    Early COVID-19 Vaccine ‘likely to be imperfect’: UK Task Force

    UK Vaccines Taskforce Chair Kate Bingham said on Tuesday that the first generation of COVID-19 vaccines “is likely to be imperfect” and that they “might not work for everyone”.

    “However, we do not know that we will ever have a vaccine at all. It is important to guard against complacency and over-optimism,” Bingham wrote in a piece published in The Lancet medical journal.

    “The first generation of vaccines is likely to be imperfect, and we should be prepared that they might not prevent infection but rather reduce symptoms, and, even then, might not work for everyone or for long,” she added.

    Bingham wrote that the Vaccine Taskforce recognises that “many, and possibly all, of these vaccines could fail”, adding the focus has been on vaccines that are expected to elicit immune responses in the population older than 65 years.

    She said that the global manufacturing capacity for vaccines is vastly insufficient for the billions of doses that are needed and that the United Kingdom’s manufacturing capability to date has been “equally scarce”.

    Earlier on Tuesday, a study by scientists at Imperial College London found that antibodies against the novel coronavirus declined rapidly in the British population during the summer, suggesting protection after infection may not be long-lasting and raising the prospect of waning immunity in the community.

    The Telegraph newspaper reported that the British government is working on the assumption that the second wave of coronavirus will be more deadly than the first.

  • Japan might have a vaccine for Coronavirus

    Japan might have a vaccine for Coronavirus

    The Japanese media is reporting that a drug created in Japan to treat new strains of the flu has appeared to be effective in coronavirus patients in China.

    Medical authorities have used the drug during a drug test in China reports The Guardian, and according to an official of China’s science and technology ministry, “it is clearly effective in treatment”.

    The drug, known as favipiravir, developed as a subsidiary of Fujifilm, has produced encouraging results in clinical trials in Wuhan and Shenzhen. The trials included 340 patients.

    READ MORE: All Coronavirus Updates

    In Shenzhen, patients who were given the medicine, showed negative for the virus, four days after they had tested positive. This is in comparison to people who showed negative to the virus after 11 days of testing positive. X-rays also showed improvements in lung conditions in “about 91% of the patients who were treated” with the medication, “compared to 62% of those without the drug,” reported The Guardian.

    Simultaneously, doctors in Japan were using the same drug in their studies on coronavirus patients with mild to moderate symptoms but their results suggested that it doesn’t work on people with more severe symptoms.

    RELATED: The U.S. warns coronavirus “will last 18 months or longer”

    The drug was first used in 2016 by the Japanese government as an emergency medication to counter the Ebola virus in Guinea. Since this drug was originally intended to treat the flu, it would need government approval for full use on coronavirus patients.